Monophasic estrogen-progestogen therapy and sexuality in postmenopausal women

This study aimed to evaluate the effects of monophasic estrogen-progestogen therapy on the sexuality and climacteric symptoms of postmenopausal women. A prospective, randomised, double-blind, crossover, placebo-controlled, single-centre study was carried out over a total of 12 consecutive months in...

Full description

Saved in:
Bibliographic Details
Published in:Clinical drug investigation 2007-01, Vol.27 (2), p.131-137
Main Authors: Fonseca, A M, Bagnoli, V R, Penteado, S R L, Paixão, J S, Cavalcanti, A L, Pinotti, J A
Format: Article
Language:English
Subjects:
Adult
Cross-Over Studies
Double-Blind Method
Drug Combinations
Estradiol - therapeutic use
Female
Hormone Replacement Therapy
Hot Flashes - drug therapy
Humans
Libido - drug effects
Middle Aged
Norethindrone - analogs & derivatives
Norethindrone - therapeutic use
Personal Satisfaction
Postmenopause - drug effects
Postmenopause - physiology
Progesterone Congeners - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study aimed to evaluate the effects of monophasic estrogen-progestogen therapy on the sexuality and climacteric symptoms of postmenopausal women. A prospective, randomised, double-blind, crossover, placebo-controlled, single-centre study was carried out over a total of 12 consecutive months in 40 postmenopausal women with an intact uterus who had no contraindications to hormone therapy. Patients received 17beta-estradiol 2mg in combination with norethisterone acetate 1mg (Cliane) daily for 6 months or one placebo tablet daily for 6 months. The tablets were identical in appearance. After 6 months, the groups were crossed over and the patients were followed up for another 6 months. The groups were homogenous with respect to age, height, bodyweight, body mass index and race. For the statistical analysis, the group receiving hormone therapy was referred to as group A and the placebo group was designated group B, irrespective of the placebo/hormone therapy sequence. In group A there were fewer hot flashes (F=22.85, p
ISSN:1173-2563
1179-1918
DOI:10.2165/00044011-200727020-00006